JW Therapeutics competitors and similar companiesClear all

JW Therapeutics's competitors and similar companies include Neovii, Eutilex, Alpha Tau Medical and Foghorn Therapeutics.
JW Therapeutics
JW Therapeutics
JW Therapeutics is a biotech company focusing on clinical cell therapy technology.
Neovii
Neovii
Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.
Eutilex
Eutilex
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology.
Alpha Tau Medical
Alpha Tau Medical
Alpha Tau Medical focuses on research, development, and commercialization of diffusing alpha-emitters radiation therapy (DaRT) for the treatment of solid cancer tumors.
Foghorn Therapeutics
Foghorn Therapeutics
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
Founding Date
Founding Date
2016
Founding Date
2003
Founding Date
2015
Founding Date
2016
Founding Date
2016
Type
Type
Private
Type
Private
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
CN HQ
Suzhou Shi, CN
Locations
Rapperswil-Jona, CH HQ
Gräfelfing, DE
Lexington, US
Locations
KR HQ
Locations
Tel Aviv-Yafo, IL HQ
Boston, US
Locations
Cambridge, US HQ
Cambridge, US
Employees
Employees
1026% increase
Employees
872% decrease
Employees
108
Employees
79
Employees
85
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
894
Twitter followers
914
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
7
Number of tweets (last 30 days)
11
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
2.1
Average likes per tweet (last 30 days)
2.6
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
90.91%
Alexa Website Rank
Alexa Website Rank
349818
Alexa Website Rank
701866
Alexa Website Rank
N/A
Alexa Website Rank
478309
Alexa Website Rank
284783
Employee Rating
Employee Rating
N/A
Employee Rating
N/A
Employee Rating
N/A
Employee Rating
2.7
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
₩73.5m (FY, 2021)
Revenue (est.)
N/A
Revenue (est.)
$1.3m (FY, 2021)
Net income
Net income
N/A
Net income
N/A
Net income
(₩29.6b) (FY, 2021)
Net income
N/A
Net income
($101.3m) (FY, 2021)

Funding

Latest funding round
Latest funding round
$ 90m (over 4 years ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 26m (over 2 years ago)
Latest funding round
N/A
Total funding raised
Total funding raised
$ 90m
Total funding raised
N/A
Total funding raised
$ 18.9m
Total funding raised
$ 55m
Total funding raised
$ 50m
For sources of this data, please see the company profile

View company profiles

Neovii
HQ
Rapperswil-Jona, CH
Employees
87↓ 2% decrease

Neovii is a company specializing in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology and oncology.

View company
Eutilex
HQ
KR
Employees
108

Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy and antibody therapeutics based on its proprietary immunotherapy technology.

View company
Alpha Tau Medical
HQ
Tel Aviv-Yafo, IL
Employees
79

Alpha Tau Medical focuses on research, development, and commercialization of diffusing alpha-emitters radiation therapy (DaRT) for the treatment of solid cancer tumors.

View company
Foghorn Therapeutics
HQ
Cambridge, US
Employees
85

Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.

View company